Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger ...(focuses on the core areas of commercial ...),Health

Date:9/30/2009

focuses on the core areas of commercial activity: capital markets; corporate and M&A; finance and banking; real estate; tax; pensions and employment; litigation and dispute resolution. Clifford Chance has 29 offices in 20 countries with some 3,600 legal advisers. The Firm also operates a 'best friends' arrangement with AZB & Partners in India and with Lakatos, Koves & Partners in Hungary, and a co-operation agreement with Al-Jadaan & Partners Law Firm in Saudi Arabia.

    Media Contact:
    Ashley A. Hill
    (212) 880-5638
    ashley.hill@cliffordchance.com

SOURCE Clifford Chance

'/>"/>

SOURCE Clifford Chance Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
3. Portable CT Increases Chance of Stroke Survival and Recovery
4. Northern California Cancer Centers First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival
5. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
11. MannKind Addresses Pfizers Announcement Regarding Exubera